Table S1. Characteristics of the study	participants
--	--------------

Characteristic	No steatosis	Steatosis	P-value
Ν	36	36	
Age – y	12.5 (10.2-14.7)	14.0 (12.0-16.0)	0.0096
Male – no. (%)	16 (44.4)	20 (55.7)	0.4798
Metabolic Syndrome – no. (%)	2 (5.6)	8 (22.2)	0.0850
Severe obesity – no. (%)	12 (33.3)	19 (52.8)	0.1530
BMI/age- (Z- score)	2.59 (2.17 – 3.14)	3.01 (2.57 – 3.44)	0.0122
WC > $90^{\text{th}}$ percentile – no. (%)	26 (72.2)	31 (86.1)	0.2450
Waist circumference (WC) - cm	87.8 (82.3 - 97.5)	101.0 (92.5 – 110.1)	0.0003
Systemic Arterial Hypertension - no. (%)	2 (5.6)	10 (27.8)	0.0238
Systolic blood pressure - mmHg	115.5 (107.5 – 121.5)	114.5 (105.5 – 123.0)	0.8791
Diastolic blood pressure - mmHg	70.0 (64.5 – 73.5)	70.0 (62.5 – 79.5)	0.5614

Data represent median and interquartile range (continuous variables) or frequency (categorical variables). The Mann-Whitney *U* test was used to compare age, anthropometric data and blood pressure distribution between the groups and the Fisher's exact test was used to compare frequency of male individuals and comorbidities frequency between the groups. *P*-values in bold font are statistically significant.

	1414400 01 111			
Biomarker	Unit	No steatosis	Steatosis	P-value
Hematocrit	%	38.9	38.8	0.4014
		(36.5-40.4)	(37.5-41.5)	
Hemoglobin	g/dL	13.1	13.2	0.1969
		(12.3-13.8)	(12.7-14.2)	
Glucose	mg/dL	87.3	87.3	0.9282
		(84.1-91.8)	(84.4-91.5)	
Insulin	UI/mL	15.2	16.1	0.7270
		(9.4-24.0)	(9.5-22.4)	
Homa-IR	-	3.4	3.5	0.6769
		(2.2 - 4.9)	(2.1 – 4.5)	
Total Cholesterol	mg/dL	159.0	157.5	0.2414
		(140.5-180.0)	(123.5-181.5)	
HDL-c	mg/dL	41.0	39.35	0.0953
		(37.2-47.0)	(33.0-45.7)	
LDL-c	mg/dL	89.6	91.5	0.3440
		(79.8-113.5)	(71.0-108.3)	
Triglycerides	mg/dL	82.5	97.5	0.1990
		(71.0-124.3)	(79.0-145.5)	
Urea	mg/dL	22.0	21.0	0.4428
		(19.0-26.7)	(18.0-25.5)	
Creatinine	mg/dL	0.63	0.64	0.6563
		(0.60-0.70)	(0.57-0.79)	
AST	U/L	19.1	21.0	0.3489
		(17.0-23.9)	(18.0-26.5)	
ALT	U/L	16.0	24.4	0.0008
		(12.2-21.8)	(18.4-33.6)	
GGT	U/L	18.0	25.0	0.0185
		(16.0-23.0)	(17.2-36.5)	
Alkaline Phosphatase	U/L	256.2	189.5	0.0514
		(134.3-327.5)	(89.5-264.8)	
Albumin	g/dL	4.4	4.45	0.3540
		(4.2-4.6)	(4.3-4.7)	
Direct Bilirubin	g/dL	0.16	0.16	0.4770
		(0.13-0.22)	(0.12-0.20)	
Indirect Bilirubin	g/dL	0.17	0.17	0.9955
TOTA	TTT ( 1	(0.10-0.24)	(0.10-0.29)	0 = 0 4 4
TSH	μUL/ml	2.2	2.0	0.5246
	/ 17	(1.6-3.0)	(1.45-3.23)	0.5500
f14	ng/dL	1.2	1.16	0.5580
<b>T</b>	/ Τ	(1.0-1.3)	(1.06-1.26)	0.0771
Ferritin	ng/mL	68.1	72.2	0.2771
	/ τ	(43.7-81.9)	(42.4-108.5)	0.4050
Vitamin D	ng/mL	21./	20.5	0.4850
CDD	/ 11	(19.1-24.8)	(18.1-24.3)	0.0140
us-CRP	mg/dL	0.25	0.25	0.9148
TCE 0	/ T	(0.10-0.62)	(0.09-0.50)	0.0001
IGF-þ	pg/mL	4.58	539.U	0.0001
ЦО 1	n	(0.11-15.3)	(31.3-706.1)	0.2294
ПО-1	pg/mL	4/.7 (12.1.09.4)	24.1 (11.1.(2.0)	0.3384
		(12.1-70.4)	(11.1-00.7)	

Table S2. Median values of measured plasma markers

The Mann-Whitney U test was used to compare continuous variables between the groups. P-values in bold font were statistically significant.

	Hepatic steatosis						
Parameter	Unit	No	Mild	Moderate/ Severe	P-value	result	
Body Mass Index	Kg/m <sup>2</sup>	28.6	31.4	38.1	0.0005	b	
		(26.2-33.2)	(28.6-34.9)	(35.1-40.1)			
BMI/age	Z score	2.6	2.9	3.4	0.0080	b	
		(2.2 – 3.1)	(2.6 – 3.3)	(3.1 – 3.7)			
Hematocrit	%	38.9	38.4	39.4	0.6665	ns	
		(36.5-40.4)	(37.4-41.9)	(37.8-40.9)			
Hemoglobin	g/dL	13.1	13.2	13.2	0.3985	ns	
		(12.3-13.8)	(12.6-14.4)	(12.8-14.2)			
Glucose	mg/dL	87.3	85.9	89.7	0.2948	ns	
		(84.1-91.8)	(83.8-90.5)	(86.5-91.8)			
Insulin	UI/mL	15.2	16.8	15.4	0.8844	ns	
II ID		(9.4-24.0)	(9.34-22.7)	(9.5-21.4)	0.0554		
Homa-IR	-	3.4	3.7	3.3	0.8574	ns	
	( 17	(2.2 – 4.9)	(2.1 – 4.8)	(2.6 – 4.5)	0.4020		
Total Cholesterol	mg/dL	159.0	157.5	154	0.4939	ns	
LIDI	/ 17	(140.5-180.0)	(119.3-181.5)	(135.8-180.5)	0.050(		
HDL	mg/dL	41.0	40.5	37.5	0.0736	ns	
IDI		(37.2-47.0)	(34.7-46.8)	(30.5-40.0)	0 4942		
LDL	mg/dL	89.6 (70.8.112.5)	86.5	95.5	0.4842	ns	
Tui al vaani daa	ma/dI	(79.8-113.5)	(68.0-108.3)	(83.3-116.0)	0 4279		
Trigiycerides	mg/aL	82.3 (71.0.124.2)	97.5 (74 E 10E 8)	107.5	0.4278	ns	
Uroo	ma/dI	(71.0-124.3)	(74.5-195.8)	(81.0-134.3)	0.6584	200	
Ulea	mg/uL	(10, 0, 26, 7)	(17.0, 27.7)	(10.0.25.5)	0.0384	115	
Creatinina	ma/dI	(19.0-20.7)	(17.0-27.7)	(19.0-23.3)	0.8367	nc	
Creatinine	ilig/uL	(0.60.0.70)	(0.57, 0.78)	(0.55.0.80)	0.0307	115	
ΔST	II/I	19.1	19.5	(0.00-0.00)	0 2614	ne	
7101	0/1	(17.0-23.9)	(17.0-27.7)	(20, 2-24, 7)	0.2014	115	
ALT	U/L	16.0	22.0	25.0	0.0016	a: b	
	0/2	(12 2-21 8)	(15.0-33.6)	(21.0-37.5)	010010	u, 2	
GGT	U/L	18.0	25.0	25.0	0.0576	ns	
	-,	(16.0-23.0)	(17.0-35.0)	(20.5-37.7)			
Alkaline	U/L	256.2	206.4	138.0	0.0662	ns	
Phosphatase		(134.3-327.5)	(104.0-310.8)	(81.0-248.5)			
Albumin	g/dL	4.4	4.45	4.45	0.6382	ns	
	0	(4.2-4.6)	(4.30 - 4.70)	(4.15-4.60)			
Direct Bilirubin	g/dL	0.16	0.15	0.17	0.7231	ns	
		(0.13-0.22)	(0.11-0.19)	(0.12-0.21)			
Indirect Bilirubin	g/dL	0.17	0.17	0.17	0.8829	ns	
		(0.10-0.24)	(0.05-0.25)	(0.10-0.42)			
TSH	µUL/mL	2.2	2.3	1.48	0.0730	ns	
		(1.6-3.0)	(1.8-3.35)	(1.35-1.71)			
FT4	ng/dL	1.2	1.2	1.13	0.7506	ns	
		(1.0-1.3)	(1.05-1.28)	(1.07-1.21)			
Ferritin	ng/mL	68.1	73.7	72.2	0.4829	ns	
		(43.7-81.9)	(44.9-120.0)	(41.2-101.8)			
Vitamin D	ng/mL	21.7	20.5	20.6	0.7230	ns	
CDD	/ 17	(19.1-24.8)	(18.2-24.2)	(14.9-24.4)	0 =0=1		
CRP	mg/dL	0.25	0.20	0.46	0.5051	ns	
TCE 0		(0.10-0.62)	(0.08-0.41)	(0.10-0.76)	0.0004	1	
IGF-β	pg/mL	4.58	579.6	521.8	0.0001	a; b	
UO 1	na/T	(0.11-15.3)	(20.67-796.2)	(73.52-637.3)	0 5295		
110-1	pg/mL	47.9 (12 9-08 1)	22.0 (11.0.65.5)	30.32 (10.0_110.6)	0.5385	ns	
		(14.2-20.4)	(11.0-00.0)	(10.0-110.0)			

Table S3. Concentration of parameters according to grade of hepatic steatosis

Data represent medians and interquartile ranges. Data was analyzed using Kruskal-Wallis test with Dunn's multiple comparisons. P-values in bold font were statistically significant. *Ad hoc* comparisons with P-value <0.05: aNo steatosis vs. Mild steatosis, bNo steatosis vs. Moderate/Severe steatosis. ns: nonsignificant.



Figure S1. Overall profile of concentrations of biochemical parameters according to occurrence of hepatic steatosis and degree of obesity.

Values of indicated parameters were assessed in samples from patients without hepatic steatosis (n=36) and patients with hepatic steatosis (n=36), who were ordered according to degree of obesity. Data were Log10 transformed and z-score normalized. A hierarchical cluster analysis (Ward's method with 100X bootstrap) was employed to test whether there were differences in the overall expression profile of the biochemical parameters in the study population.



Data were analyzed using the Spearman correlation rank test. Lines represent linear curve fit with 95% confidence intervals.



Figure S3. Degree of biochemical perturbation of each biomarker according to grade of hepatic steatosis.

A one-way hierarchical cluster analysis (Ward's method with 100X bootstrap) using data on degree of biochemical perturbation calculated for each individual parameter was employed to visualize the profiles potentially associated degree of steatosis. To plot the heatmap, data were log10-transformed, and z-score normalized.



Figure S4. Degree of biochemical perturbation of each biomarker according to degree of obesity.

A one-way hierarchical cluster analysis (Ward's method with 100X bootstrap) using data on degree of biochemical perturbation calculated for each individual parameter was employed to visualize the profiles potentially associated degree of obesity. To plot the heatmap, data were log10-transformed, and z-score normalized.